Form 4: Amylyx Pharmaceuticals Co-CEO Justin B. Klee Reports Acquisition of Shares and Stock Options

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports acquiring shares and stock options in the company.

Summary

• On March 6, 2025, Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, reported acquiring 180,118 shares of common stock and 270,177 stock options.
• The common stock was acquired through a restricted stock unit (RSU) award.
• The RSUs vest in four equal annual installments starting March 1, 2026, contingent upon continued service.
• The stock options have an exercise price of $3.61.
• 25% of the stock options vest on March 1, 2026, with the remaining shares vesting monthly over the subsequent 36 months, also contingent upon continued service.
• Following the reported transactions, Klee beneficially owns 3,376,766 shares of common stock and 270,177 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock and option acquisitions, which doesn't inherently indicate positive or negative sentiment, but the acquisition of shares by the CEO could be seen as a positive sign.

Positives

• The acquisition of shares and stock options by the Co-CEO could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Form 4 filings are a routine part of insider trading disclosures and provide transparency into the transactions of company executives and directors. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding the company's prospects.

Key Dates